Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia

Xavier Thomas Hospices Civils de Lyon, Hematology, Lyon-Sud Hospital, Pavillon Marcel Bérard, France Abstract: Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the sur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Thomas X
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/89abc1d5f8824785adfdca466fa9eea8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:89abc1d5f8824785adfdca466fa9eea8
record_format	dspace
spelling	oai:doaj.org-article:89abc1d5f8824785adfdca466fa9eea82021-12-02T00:25:54ZProfile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia1179-9889https://doaj.org/article/89abc1d5f8824785adfdca466fa9eea82014-04-01T00:00:00Zhttp://www.dovepress.com/profile-of-inotuzumab-ozogamicin-and-its-potential-in-the-treatment-of-a16517https://doaj.org/toc/1179-9889 Xavier Thomas Hospices Civils de Lyon, Hematology, Lyon-Sud Hospital, Pavillon Marcel Bérard, France Abstract: Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the surface of leukemia cells in ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, which has shown efficacy in patients with lymphomas, has also shown encouraging activity in relapsed or refractory ALL with a high morphologic and molecular response rate. This article summarizes the current approaches to treating ALL with inotuzumab ozogamicin, based on available data from the literature. Keywords: monoclonal antibody, inotuzumab ozogamicin, CMC-544, acute lymphoblastic leukemia, targeted therapyThomas XDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 1-8 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Thomas X Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
description	Xavier Thomas Hospices Civils de Lyon, Hematology, Lyon-Sud Hospital, Pavillon Marcel Bérard, France Abstract: Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the surface of leukemia cells in ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, which has shown efficacy in patients with lymphomas, has also shown encouraging activity in relapsed or refractory ALL with a high morphologic and molecular response rate. This article summarizes the current approaches to treating ALL with inotuzumab ozogamicin, based on available data from the literature. Keywords: monoclonal antibody, inotuzumab ozogamicin, CMC-544, acute lymphoblastic leukemia, targeted therapy
format	article
author	Thomas X
author_facet	Thomas X
author_sort	Thomas X
title	Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
title_short	Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
title_full	Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
title_fullStr	Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
title_full_unstemmed	Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
title_sort	profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/89abc1d5f8824785adfdca466fa9eea8
work_keys_str_mv	AT thomasx profileofinotuzumabozogamicinanditspotentialinthetreatmentofacutelymphoblasticleukemia
_version_	1718403748763533312

Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia

Ejemplares similares